Immunai

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas.

We recently published a list of Top 8 AI News Updates Investors Should Not Miss. In this article, we are going to take a look at where Nano-X Imaging Ltd. (NASDAQ:NNOX) stands against other top AI news updates investors should not miss.

Healthcare professionals, marketers and institutions spend nearly 40 per cent of their time creating and publishing content, which diverts resources from patient care, research and innovation.

Biotech company Immunai, which developed an AI-based immune system mapping technology for drug development, announces the appointment of Dr. Mikael Dolsten to its board of directors.

In recent years, the rapid advancement of artificial intelligence (AI) has ushered in a transformative era in medical and biological research.

Another company involved in using AI to repurpose failed drugs - as well as drugs that have already been approved - is BioXcel Therapeutics. Unlike Ignota, however, the company focuses on compounds that have already demonstrated safety in prior clinical trials, but have been discontinued by their developers for various other reasons.

A Boston drug discovery company that uses AI has hit unicorn valuation. It uses transformer diffusion models, which its CEO says can "understand the concept of time and how you change, from cradle to grave.

UNC Charlotte researchers are contributing to pioneering breakthroughs in cancer therapeutics, communicable disease forecasting and prevention, optical applications for health care, and use of AI and other innovative computational tools — and more.